Artificial intelligence, women’s health, and partnerships are among the highlights for the second quarter of 2026. Multiple firms made headlines as they showcased their new ventures and deals that reflect the rapidly changing environment of the healthtech industry.
From Amazon’s newest drug discovery platform to large funding rounds and healthcare company mergers, here’s a look at some of the developments shaping the industry right now.
Amazon launches AI-powered drug discovery platform
AI is steadily becoming a core part of how new medicines are developed. Amazon Web Services (AWS) recently introduced Amazon Bio Discovery, a platform designed to accelerate drug discovery by combining biological AI models with laboratory testing.
The platform gives scientists and researchers access to over 40 biological foundation models that can help generate, evaluate, and optimise potential drug candidates. It also includes AI agents that assist scientists with model selection, data preparation, and result interpretation.
This makes advanced AI tools more accessible even to teams without deep AI expertise.
What makes the platform particularly interesting is its lab-in-the-loop approach. Once candidate molecules are designed digitally, they are sent to laboratory partners for synthesis and testing. The resulting experimental data is then fed back into the platform, helping refine future predictions and designs.
AWS says the platform is intended for pharmaceutical companies, biotech firms, and academic researchers.
Among the early adopters of Amazon Bio Discovery are Bayer, the Broad Institute, Memorial Sloan Kettering Cancer Centre, and Voyager Therapeutics.
Oura confidentially files for IPO in the US
The wearables market could soon see one of its biggest public listings with Oura getting ready for another big milestone. The wearable healthtech firm has filed confidentially to make its debut on the US stock market in what would be its next stage of development.
Oura isn’t the same company it used to be five years ago. Currently on track to cross the 5 million paid members barrier, the company has already sold more than 5.5 million rings globally and is valued at about $11 billion.
The company that started life as a simple tracker for sleep has evolved into something much bigger.
Specifically, Oura Ring offers several different products and solutions related to a few key segments:
- Sleep and recovery
- Stress and heart health
- Women’s health insights
- Health features powered by AI
- Clinician consultations in partnership with Counsel Health
The IPO plans also reflect a broader trend: investors continue to see significant long-term potential in consumer health platforms that generate continuous health data.
Chai Discovery partners with Pfizer to accelerate AI-driven drug discovery
The race to apply AI in drug discovery is heating up, and pharmaceutical companies are increasingly moving beyond pilots and proofs of concept.
This month, Chai Discovery struck a licensing deal with Pfizer, allowing the pharma giant to leverage the capabilities of Chai’s AI platform and Chai-3 model.
The agreement allows Pfizer to integrate Chai’s technology directly into its research and drug discovery workflows. The collaboration will also involve training custom AI models using Pfizer’s proprietary datasets.
The partnership is expected to accelerate the development of biologics and overcome challenges associated with drug discovery for hard-to-drug targets. According to Chai, its models can significantly reduce the time required for discovery that may have taken months or even years before.
Key components of the deal include:
- Access to Chai-3
- Custom AI model training based on Pfizer’s data
- Integration with Pfizer’s research workflow
Partnerships like this are becoming increasingly common as pharmaceutical companies shift from exploring AI’s potential to deploying it in real-world R&D programmes.
Melinda French Gates pledges $215 million for women’s health
Women’s health continues to gain momentum as one of healthcare’s fastest-growing areas of investment.
Melinda French Gates recently announced a $215 million commitment through Pivotal, focused on improving health outcomes during reproductive and midlife stages.
The funding aims to address longstanding gaps in research, care access, and treatment options that have historically received less attention than other areas of medicine.
The following are among those focus areas:
- Reproductive and Maternal Health
- Access to Contraceptives
- Menopause and Perimenopause Treatment
- Research into Midlife Women’s Diseases
- Mother’s Mental Health
“For too long, a lack of money has forced organisations fighting for women’s rights into a defensive posture while the enemies of progress play offence. I want to help even the match.”
–Melinda French Gates
This latest funding makes the overall sum of the French Gates’ contribution to women’s health care reach more than $600 million over the past two years.
Mayo Clinic and Microsoft collaborate on healthcare-focused AI model
Developments involving AI kept making headlines this quarter. Mayo Clinic and Microsoft joined hands to build a unique AI model for healthcare providers.
The model will be trained using Mayo Clinic’s extensive clinical expertise and de-identified patient data, combined with Microsoft’s advanced AI and cloud infrastructure. It will help healthcare professionals improve clinical reasoning, support decision-making, and deliver more personalised patient care.
Unlike other generic AI models that can be used in various ways, this initiative focuses exclusively on healthcare applications, enabling the model to better understand complex medical data and workflows. While Mayo Clinic will own the model, Microsoft intends to offer it to other organisations via Azure Foundry APIs.
Apollo Cradle and Cloudnine to merge in ₹1,550 crore deal
Healthcare consolidation remains another defining trend across the industry.
In India, Apollo Cradle and Apollo Fertility will reportedly merge with Cloudnine in a deal worth ₹1,550 crore to become one of India’s leading maternity and fertility care platforms. This exponential valuation is represented through a mix of cash and a 9.9% equity stake in the combined entity.
Some of the key outcomes include:
- A combined network of 55+ centres
- Expanded maternity and fertility services
- Stronger presence across major Indian markets
- A 9.9% ownership stake for Apollo Health and Lifestyle
The merger highlights how specialised healthcare providers are increasingly seeking scale to improve reach, operational efficiency, and patient access.
What this means for the industry
Taken together, these developments point to several larger shifts happening across healthcare:
- AI is moving from experimentation to large-scale deployment.
- Big technology companies are investing deeper into healthcare.
- Wearables are evolving into long-term health platforms.
- Women’s health is attracting more capital and attention than ever before.
- Infrastructure and B2B healthcare platforms are becoming critical ecosystem enablers.
- Healthcare providers are consolidating to build larger, specialised networks.
- The industry is increasingly focused on implementation rather than innovation for innovation’s sake.
In short, healthtech is entering a more mature phase. One where the conversation is no longer about what’s possible, but about what’s already being built, deployed, and scaled.
-By Shivam Sharma and the AHT Team
